Zelboraf 240 mg Tablet

Description

Zelboraf 240 mg Tablet contains vemurafenib, a targeted anticancer medicine classified as a BRAF kinase inhibitor. It is used in the treatment of certain cancers that carry a specific mutation in the BRAF gene, most commonly BRAF V600 mutation–positive melanoma. This mutation causes abnormal signaling that promotes uncontrolled growth of cancer cells. By targeting this pathway, vemurafenib may help slow tumor growth when used as prescribed by a qualified healthcare professional. Zelboraf is typically prescribed for patients whose tumors have been confirmed to carry the BRAF V600 mutation through appropriate diagnostic testing. The medicine is taken orally and is usually part of a treatment plan managed by an oncologist. In some cases, it may be used in combination with other cancer therapies depending on clinical guidelines and patient-specific factors. Patients receiving treatment with

Benefits

• Targets the BRAF V600 mutation, a driver of tumor growth in some cancers

• Precision oncology therapy based on tumor genetic profiling

• Oral tablet formulation for convenient administration

• May help slow cancer progression in patients with confirmed BRAF mutation

• Used in modern targeted therapy regimens

Indications and Usage

Zelboraf (vemurafenib) may be prescribed for:

• Unresectable or metastatic melanoma with BRAF V600 mutation

• Certain patients with Erdheim-Chester disease (ECD) with BRAF mutation

• Treatment based on confirmed genetic testing for BRAF mutation

Use is determined by an oncologist following molecular diagnostic testing.

How it Works

Vemurafenib works by inhibiting the BRAF protein kinase, specifically the mutated BRAF V600 variant found in certain cancers. The BRAF protein is part of the MAPK signaling pathway, which regulates cell growth and survival. When mutated, this pathway becomes overactive, causing uncontrolled cell division.

By blocking the activity of mutated BRAF proteins, vemurafenib disrupts abnormal signaling that promotes cancer cell proliferation. This targeted mechanism can help slow tumor growth in patients whose cancers carry the BRAF V600 mutation when the medicine is used as prescribed and monitored by an oncology specialist.

Dosage & Administration

• Zelboraf tablets are taken orally, typically twice daily, unless directed otherwise by a healthcare professional.

• Tablets should be swallowed whole with water.

• The medicine may be taken with or without food.

• Dose adjustments may be required depending on tolerance and side effects.

• Treatment continues until disease progression or unacceptable toxicity, as determined by the oncologist.

Side Effects

Common side effects

• Joint pain (arthralgia)

• Rash

• Fatigue

• Hair thinning or hair loss

• Photosensitivity (increased sensitivity to sunlight)

• Nausea

Serious side effects

• Severe skin reactions

• Secondary skin cancers such as cutaneous squamous cell carcinoma

• Heart rhythm abnormalities (QT prolongation)

• Liver function abnormalities

• Eye problems such as uveitis

Patients should seek medical attention if serious symptoms occur.

Warning and Precaution

• Risk of secondary skin cancers, requiring regular dermatologic monitoring

• Increased photosensitivity, requiring sun protection

• Possible heart rhythm abnormalities (QT prolongation)

• Liver function abnormalities may occur

• Eye disorders such as uveitis or retinal issues

• Inform healthcare providers about all medications and supplements being used

• Pregnancy should be avoided during treatment

Patient Guidance

• Take the medicine exactly as prescribed by your oncologist

• Attend scheduled monitoring appointments and laboratory tests

• Protect skin from sun exposure using sunscreen and protective clothing

• Report symptoms such as new skin lesions, vision changes, or severe rash

• Inform your doctor about all medications and supplements you take

• Do not stop treatment without consulting your healthcare provider

Clinical Trial & Approvals

Vemurafenib has been evaluated in several clinical trials for patients with BRAF V600 mutation–positive melanoma. The BRIM-3 clinical trial demonstrated improved survival outcomes compared with certain traditional chemotherapy treatments. Based on these results, vemurafenib received regulatory approvals from agencies including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for specific oncology indications.

References